Treatment Guidelines from The Medical Letter
FROM
ISSUE
106
Drugs for HIV Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others.1-3 Resistance testing is now recommended when antiretroviral drugs are started.4 Increases in HIV RNA levels ("viral load") while on therapy may indicate development of drug resistance, requiring further testing and a change in the treatment regimen. Antiretroviral drugs interact with each other and with many other drugs; complete information on these interactions is available at www.aidsinfo.nih.gov.

Antiretroviral treatment regimens usually include a "backbone" and a "base". The backbone is typically two nucleoside reverse transcriptase inhibitors (NRTIs). The base can be a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for HIV Infection
Article code: 106a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian